Top-News
Biotechnologie USA

Scholar Rock Holding Aktie

Aktie
WKN:  A2JMQW ISIN:  US80706P1030 US-Symbol:  SRRK
40,00 €
-2,20 €
-5,21%
11.12.24
Handeln Depot/Watchlist
Aktienanzahl *
72,14 Mio.
Marktkapitalisierung *
2,73 Mrd. €
Streubesitz
0,51%
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 11.12.2023

Scholar Rock Holding News

12.11.24 - Businesswire
Scholar Rock Reports Third Quarter 2024 Financial Results and Highlights Business Progress
Scholar Rock (NASDAQ: SRRK), a late-​stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic ...
04.11.24 - Businesswire
Scholar Rock Announces New Preclinical Data for SRK-439 Showing Significant Lean Mass Increase and Enhanced Fat Mass Loss with Metformin
Scholar Rock (NASDAQ: SRRK), a late-​stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic ...
01.11.24 - Businesswire
Scholar Rock to Host Conference Call to Discuss Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024
Scholar Rock (NASDAQ: SRRK), a late-​stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic ...
31.10.24 - Businesswire
Scholar Rock to Participate in Upcoming Investor Conferences
Scholar Rock (NASDAQ: SRRK), a late-​stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic ...
22.10.24 - Businesswire
Scholar Rock Announces Closing of Full Exercise of Option to Purchase Additional Shares in Public Offering
Scholar Rock Holding Corporation (Nasdaq: SRRK), a late-​stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), ...
18.10.24 - wallstreetONLINE Redaktion
Markt verfünffacht sich: Diese 5 Konzerne attackieren Novo, Lilly auf dem lukrativen Adipositas-Markt
Auch wenn alle nur noch über KI reden, der Markt für Gewichtsverlust-​Mittel explodiert regelrecht. Einige Unternehmen haben gute Chancen, den Marktführern gefährlich zu ...
18.10.24 - wallstreetONLINE Redaktion
Neue Medikamente im Rennen: Diese 5 Konzerne attackieren Novo, Lilly auf dem lukrativen Adipositas-Markt
Auch wenn alle nur noch über KI reden, der Markt für Gewichtsverlust-​Mittel explodiert regelrecht. Einige Unternehmen haben gute Chancen, den Marktführern gefährlich zu ...
09.10.24 - Businesswire
Scholar Rock Announces Pricing of Upsized $300 Million Public Offering of Common Stock and Pre-Funded Warrants
Scholar Rock Holding Corporation (Nasdaq: SRRK), a late-​stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), ...
08.10.24 - Der Aktionär
Scholar Rock rockt die Börse: 362 Prozent an einem (!) Tag – so geht es jetzt weiter
07.10.24 - Businesswire
Scholar Rock Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Scholar Rock Holding Corporation (Nasdaq: SRRK), a late-​stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), ...
07.10.24 - Der Aktionär
AKTIONÄR‑Altempfehlung Scholar Rock explodiert 235 Prozent – die Hintergründe!
07.10.24 - Businesswire
Scholar Rock Reports Apitegromab Meets Primary Endpoint in Phase 3 SAPPHIRE Study in Patients with Spinal Muscular Atrophy (SMA)
Scholar Rock (NASDAQ: SRRK), a late-​stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic ...
27.08.24 - wallstreetONLINE Redaktion
25 Milliarden-Dollar-Markt: Viking, Amgen & Co: 6 Aktien, die die 2. Adipositas-Welle dominieren könnten!
Eli Lilly und Novo Nordisk dominieren zwar den Markt für Adipositas-​Medikamente. Die erfolgreichsten Konkurrenten könnten aber bis zu 20 Prozent des lukrativen Marktes erobern, ...
27.08.24 - wallstreetONLINE Redaktion
25 Milliarden-Dollar-Markt: Viking, Amgen & Co: 6 Unternehmen für die nächste Adipositas-Welle!
Eli Lilly und Novo Nordisk dominieren zwar den Markt für Adipositas-​Medikamente. Die erfolgreichsten Konkurrenten könnten aber bis zu 20 Prozent des lukrativen Marktes erobern, ...
20.01.24 - Der Aktionär
Adipositas: Dick im Geschäft
12.07.22 - PR Newswire
Thinking about buying stock in Inmode, Evofem Biosciences, Scholar Rock, Verrica Pharmaceuticals, or Indonesia Energy?
Thinking about buying stock in Inmode, Evofem Biosciences, Scholar Rock, Verrica Pharmaceuticals, or Indonesia Energy? PR Newswire
03.08.21 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Scholar Rock Holding Corporation - SRRK
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Scholar Rock Holding Corporation - SRRK PR Newswire
19.04.21 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Scholar Rock Holding Corporation - SRRK
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Scholar Rock Holding Corporation - SRRK PR Newswire
11.04.21 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Scholar Rock Holding Corporation - SRRK
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Scholar Rock Holding Corporation - SRRK PR Newswire
29.10.20 - PR Newswire
Thinking about buying stock in Scholar Rock Holding, Electrameccanica Vehicles, Verastem, Oncolytics Biotech, or Cisco Systems?
Thinking about buying stock in Scholar Rock Holding, Electrameccanica Vehicles, Verastem, Oncolytics Biotech, or Cisco Systems? PR Newswire

Newssuche

Videos

newspaper
10.12.24 -10,01%
Technical Trading: Bitcoin Short Chance, weil
Bitcoin Short Typ: Turbo Open End WKN: VC7P6B Hebel: 2,20 Laufzeit: OpenEnd Einstieg: Market ... Mehr »